HGEN News and Press, Humanigen Inc. From 07/25/23

2023-07-25 08:29:09 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Humanigen (NASDAQ: HGEN ) stock is falling hard on Tuesday after the company warned investors it can’t keep listing requirements . According to a filing from the ...

2023-07-25 06:54:08 ET Nano-cap biotech Humanigen ( NASDAQ: HGEN ) fell ~70% pre-market Tuesday after announcing that Nasdaq has decided to delist its shares from the exchange and the company is evaluating all strategic options, including a potential bankruptcy. Accordingly,...

Of the 14 participants enrolled and treated with lenzilumab plus azacitidine, ten are evaluable with three to eighteen months of follow-up and all ten have had a rapid clinical response Building upon previously reported positive clinical responses, these additional data demonstrate statisti...

2023-04-14 12:38:13 ET Trading penny stocks can appeal to investors, but it’s essential to proceed with caution when investing in these assets. They inherently possess risks that may lead to considerable losses if not managed prudently. A primary factor drawing investors to pen...

CMML is an aggressive, poorly understood cancer; approximately 20% of patients survive three years from diagnosis Eleven subjects dosed with lenzilumab and with current standard of care, azacitidine Six evaluable subjects, including those with high risk CMML, demonstrated clinical benef...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: f11photo/Shutterstock.com We’re starting off another day of trading with a breakdown of the biggest pre-market stock movers for Wednesday! Moving stocks are withdrawn offerings, earnings reports, and more...

Humanigen press release ( NASDAQ: HGEN ): Q3 GAAP EPS of -$0.23 misses by $0.04 . Revenue of $0.22M (-78.8% Y/Y) misses by $0.13M . For further details see: Humanigen GAAP EPS of -$0.23 misses by $0.04, revenue of $0.22M misses by $0.13M

Short Hills, New Jersey--(Newsfile Corp. - November 14, 2022) - Humanigen, Inc. (Nasdaq: HGEN) (Humanigen), a clinical-stage biopharmaceutical company focused on developing lenzilumab (LENZ ® ), a first-in class antibody that neutralizes granulocyte-macrophage colony-stimulating factor (G...

Short Hills, New Jersey--(Newsfile Corp. - November 10, 2022) - Humanigen, Inc. (Nasdaq: HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on preventing and treating certain inflammatory and oncological conditions, today announced that Cameron Durrant, MD, MBA, Chairman &...

Short Hills, New Jersey--(Newsfile Corp. - October 31, 2022) - Humanigen, Inc. (Nasdaq: HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on preventing and treating certain inflammatory and oncological conditions, today announced it has engaged SC&H Capital, an affili...